Benchside to Bedside: Imaging agents for cancer diagnosis (Garima Singh, ROTOP Pharmaka GmbH)
Mar 18, 2021 from 05:00 PM to 06:00 PM
R&D Project Manager, ROTOP Pharmaka GmbH, Dresden, Germany
With the aim of multimodal imaging in mind, the project “Functionalized Bispidines and Ultrasmall Silicon Nanoparticles for Cancer Imaging” dealt with the surface decoration of the ultrasmall silicon nanoparticles of size up to 5 nm. These novel nanoparticles were modified by radionuclide chelators for PET imaging, infrared dyes for optical imaging and biomolecules to target cancer tumors via covalent linkages. A size of < 10 nm is crucial for a diagnostic biomarker to be renally excretable and to avoid its accumulation in other organs. These extremely hydrophilic and biocompatible dual modal imaging agents displayed a rapid renal clearance in vivo with negligible tissue accumulation within 1 hour of intravenous administration.
The bispidine-based bifunctional chelating agents also established their strong presence in the field of Copper-II radionuclide chemistry. The magic pair of radioactive Cu-64 and Cu-67 can be used for theragnostic purposes with these robust ligands for the detection and radiotherapy of the cancer tumors by means of PET/SPECT techniques.
The pharmaceutical market of cancer diagnostics thrives on such robust and biocompatible small molecules with high efficacy and economical value with a short duration of radiation exposure to the patients.
Access to the video meeting and further information.
